10,200 Shares in Akoya Biosciences, Inc. (NASDAQ:AKYA) Bought by State Board of Administration of Florida Retirement System

State Board of Administration of Florida Retirement System bought a new position in Akoya Biosciences, Inc. (NASDAQ:AKYAGet Rating) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,200 shares of the company’s stock, valued at approximately $131,000.

Several other hedge funds also recently made changes to their positions in the company. Blue Water Life Science Advisors LP lifted its stake in shares of Akoya Biosciences by 22.1% in the 1st quarter. Blue Water Life Science Advisors LP now owns 2,088,668 shares of the company’s stock worth $22,954,000 after acquiring an additional 377,861 shares during the period. BlackRock Inc. lifted its stake in shares of Akoya Biosciences by 1.4% in the 1st quarter. BlackRock Inc. now owns 777,001 shares of the company’s stock worth $8,538,000 after acquiring an additional 10,737 shares during the period. Vanguard Group Inc. lifted its stake in shares of Akoya Biosciences by 3.8% in the 1st quarter. Vanguard Group Inc. now owns 700,823 shares of the company’s stock worth $7,702,000 after acquiring an additional 25,845 shares during the period. State Street Corp lifted its stake in shares of Akoya Biosciences by 17.5% in the 1st quarter. State Street Corp now owns 182,291 shares of the company’s stock worth $2,003,000 after acquiring an additional 27,194 shares during the period. Finally, Candriam Luxembourg S.C.A. lifted its stake in shares of Akoya Biosciences by 216.7% in the 1st quarter. Candriam Luxembourg S.C.A. now owns 159,300 shares of the company’s stock worth $1,751,000 after acquiring an additional 109,000 shares during the period. Institutional investors and hedge funds own 34.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AKYA. BTIG Research reduced their target price on shares of Akoya Biosciences to $18.00 in a research note on Tuesday, November 15th. Stephens began coverage on shares of Akoya Biosciences in a research note on Wednesday, October 5th. They issued an “overweight” rating and a $16.00 price objective for the company. TheStreet cut shares of Akoya Biosciences from a “c-” rating to a “d” rating in a research note on Tuesday, September 13th. Piper Sandler raised their price objective on shares of Akoya Biosciences from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Wednesday, August 17th. Finally, Capital One Financial began coverage on shares of Akoya Biosciences in a research note on Thursday, November 3rd. They issued an “overweight” rating and a $19.00 price objective for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $17.80.

Insider Buying and Selling at Akoya Biosciences

In other Akoya Biosciences news, Director Garry Ph.D. Nolan sold 22,191 shares of the firm’s stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $13.31, for a total transaction of $295,362.21. Following the completion of the transaction, the director now directly owns 632,893 shares in the company, valued at approximately $8,423,805.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CEO Brian Mckelligon sold 5,000 shares of Akoya Biosciences stock in a transaction dated Wednesday, September 7th. The shares were sold at an average price of $12.83, for a total transaction of $64,150.00. Following the completion of the sale, the chief executive officer now directly owns 80,000 shares in the company, valued at $1,026,400. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Garry Ph.D. Nolan sold 22,191 shares of Akoya Biosciences stock in a transaction dated Friday, September 9th. The stock was sold at an average price of $13.31, for a total transaction of $295,362.21. Following the sale, the director now owns 632,893 shares of the company’s stock, valued at $8,423,805.83. The disclosure for this sale can be found here. In the last three months, insiders sold 42,006 shares of company stock worth $556,231. 9.20% of the stock is owned by corporate insiders.

Akoya Biosciences Stock Performance

NASDAQ:AKYA opened at $12.65 on Wednesday. The company has a current ratio of 3.53, a quick ratio of 3.11 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $12.42 and a two-hundred day moving average price of $12.25. Akoya Biosciences, Inc. has a twelve month low of $8.02 and a twelve month high of $16.57. The company has a market capitalization of $480.14 million, a P/E ratio of -6.84 and a beta of 0.87.

Akoya Biosciences Profile

(Get Rating)

Akoya Biosciences, Inc, a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow.

Further Reading

Want to see what other hedge funds are holding AKYA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akoya Biosciences, Inc. (NASDAQ:AKYAGet Rating).

Institutional Ownership by Quarter for Akoya Biosciences (NASDAQ:AKYA)

Receive News & Ratings for Akoya Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akoya Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.